Live Breaking News & Updates on Multi Centre Clinical Trial
Stay updated with breaking news from Multi centre clinical trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DGAP-News: Atriva Therapeutics GmbH / Key word(s): Conference Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022 20.12.2021 / 10:00 The ....
DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics: Participation in upcoming scientific and industry conferences finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding 21.04.2021 / 16:03 Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding German Federal Ministry of Education and Research (BMBF) awards Atriva up to €11.4 million for the clinical development of a drug to treat COVID-19 Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment Targeting RNA viruses and acting in the host cell, drug candidate can retain full activity even with SARS-CoV-2 variants Therapeutic aims to inhibit replication of virus and to prevent overshooting immune response ....
DGAP-News: Atriva Therapeutics GmbH: Atriva Therapeutics Announces Changes to Management Atriva Therapeutics Announces Changes to Management 13.04.2021 / 09:30 Atriva Therapeutics Announces Changes to Management - Olaf Althaus appointed Chief Financial Officer - Stephan Stenglein, M.D., recently joined as Chief Medical Officer - Proven track record and 20+ years of experience in their respective fields of expertise Tübingen (Germany), April 13, 2021 - Atriva Therapeutics GmbH, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, today announced two changes to its management team. Olaf Althaus was appointed Chief Financial Officer, effective May 2020, while Stephan Stenglein, M.D., was named Chief Medical Officer, effective February 2021. ....